(Reuters) – Merck & Co Inc reported higher-than-expected 1/3-quarter cash, helped via cost reducing, but sales of its Januvia diabetes therapy fell, elevating extra concerns about growth possibilities for the corporate’s greatest product. The corporate mentioned on Monday it earned $1.12 billion, or 38 cents per share, within the third quarter. That when put next with $1.seventy three billion, or fifty six cents per share, within the 12 months-earlier period. With the Exception of special items, Merck earned ninety two cents per share. Analysts, on moderate, expected 88 cents per share, in keeping with Thomson Reuters I/B/E/S. Company sales fell four percent to $11. …